In this model, we specifically selected the antihistamine azelastine (AZE) to study its coadministration with the synthetic GR agonist dexamethasone (DEX) because AZE reduced the frequency of administration of inhaled GCs in chronic bronchial asthma patients.15 Importantly, three formulations containing AZE and GCs have been patented to treat allergic rhinitis, highlighting the potential therapeutic application of this drug combination in some inflammation‐associated respiratory conditions that could be linked to asthma.16, 17, 18, 19. The gene discussed is NR3C1; the disease is allergic rhinitis.